MapLight Therapeutics’ Kreitzer sells $96,024 in common stock

Anatol Kreitzer, the Chief Discovery Officer at MapLight Therapeutics, sold 12,248 shares of the company's common stock on October 15, 2026. This transaction was valued at $96,024, with each share priced at $7.84. The sale was not made arbitrarily, but rather to fulfill statutory tax withholding obligations related to the vesting of restricted stock units, as mandated by MapLight's equity incentive plans.

Following this sale, Mr. Kreitzer now holds 168,678 shares of MapLight Therapeutics common stock. This insider transaction occurs as MapLight's shares are trading near their 52-week low of $7.46, indicating a 73% decline over the past six months. Analysts view the stock as potentially undervalued, with a Fair Value of $11.22, suggesting an upside from its current price.

The platform highlights 15 additional ProTips for MapLight Therapeutics, noting that the stock is currently in oversold territory based on RSI indicators. Recently, MapLight Therapeutics announced a $150 million private placement financing, drawing interest from institutional investors. Concurrently, the company reported its second-quarter earnings.

Subsequently, various analysts adjusted their models and price targets for MapLight Therapeutics. Needham lowered its price target from $45 to $43, citing dilution concerns from the capital raise and future equity offerings. BMO Capital reduced its price target to $20 from $46, citing the ZEPHYR study results as a setback for the company's schizophrenia treatment prospects.

Canaccord also decreased its target price to $24 from $43, maintaining a Buy rating. H.C. Wainwright followed suit, lowering its price target to $26 from $45 while retaining a Buy rating. These updates reflect ongoing reactions to MapLight Therapeutics' clinical trial outcomes and financial activities.